Hansa Biopharma

Showing 8 posts of 8 posts found.

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025
General Manager Europe and International, Hansa Biopharma, vice president

Hansa Biopharma, a commercial-stage biopharmaceutical company focusing on rare immunological conditions, has announced the appointment of Max Sakkajja as Vice …

Hansa Biopharma announces positive data for Duchenne muscular dystrophy gene therapy

August 4, 2025
Research and Development Duchenne Muscular Dystophy, Hansa Biopharma, Rare Diseases, Sarepta Therapeutics, clinical trial, genetic disorder

Hansa Biopharma has announced encouraging results from its ongoing SRP-9001-104 trial, which is investigating the use of imlifidase as a …

lab

Hansa Biopharma bolsters leadership team with new executive appointments

July 31, 2025
Research and Development Chief Human Resources Officer, Chief Legal Officer, Corporate, Executive Leadership Team, Hansa Biopharma, Vice President Corporate Affairs

Hansa Biopharma has announced three senior leadership appointments to support its global expansion as well as pre-commercial activities in the …

Richard Philipson appointed as chief medical officer of Hansa Biopharma

July 9, 2025
Research and Development Hansa Biopharma, Immunology, chief medical officer, immunology

Hansa Biopharma has announced that Richard Philipson has been appointed chief medical officer, effective 14 July. Philipson will join the …

Hansa Biopharma data demonstrates potential of imlifidase in Guillain-Barré syndrome

May 15, 2025
Research and Development Guillain-Barré Syndrome (GBS), Hansa Biopharma, Immunology, Peripheral Nerve Society (PNS) Annual Meeting, Rare Diseases

Hansa Biopharma will present data from its 15-HMedIdeS-09 phase 2 study of imlifidase for treating Guillain-Barré syndrome (GBS) at the …

Hansa Biopharma appoints Maria Törnsén as chief operating officer and US president

May 14, 2025
Research and Development Corporate, Hansa Biopharma, Immunology, Pharmacy, biopharma, chief operating officer (COO), immunology

Swedish biopharma company Hansa Biopharma has appointed Maria Törnsén as chief operating officer (COO) and president US effective 19 May …

Hansa Biopharma appoints Renée Aguiar-Lucander as CEO

April 24, 2025
Research and Development CEO, Corporate, Hansa Biopharma, appointment, immunology

Swedish biopharma company, Hansa Biopharma, has announced the appointment of new chief executive officer (CEO) Renée Aguiar-Lucander, replacing Søren Tulstrup …

The Gateway to Local Adoption Series

Latest content